AI, precision medicine, biotech strategy

Turning Biomedical Innovation into Clinical and Investment-Ready Strategy

AiMi Health is a boutique advisory firm helping biotech, pharma, AI-health, and investment teams turn biomedical science, clinical data, and AI into actionable strategy for drug development, clinical trials, and capital decisions.

We help clients turn complex biology and data into clear business-critical answers by combining AI/ML expertise, oncology and precision medicine insight, and translational data strategy.

Book a Strategy Call Explore Advisory Areas

Abstract biomedical AI intelligence map connecting clinical data, precision medicine, and capital strategy

AI/ML Strategy

Precision Oncology

Clinical Trial Intelligence

Capital Advisory

Advisory Areas

High-stakes strategy across biomedical innovation, clinical development, AI, and capital decisions.

AiMi Health supports high-stakes decisions across biomedical innovation, clinical development, AI strategy, and capital-facing scientific communication.

AI & Precision Medicine Strategy

We help teams identify where AI can create meaningful value in precision medicine, oncology, clinical development, patient stratification, and biomedical evidence generation.

AI/ML strategy for biomedical and clinical use cases
Precision oncology and patient subgroup definition
AI-enabled evidence generation
Clinical NLP and biomedical knowledge mining
AI product roadmap and data asset evaluation

Biotech & Pharma Strategy

We support biotech and pharma teams in translating disease biology, biomarker logic, and clinical evidence into actionable development strategy.

Disease and indication strategy
Biomarker-driven positioning
Patient population definition
Translational data interpretation
Development roadmap support

Clinical Trial Intelligence

We help clinical development teams improve trial feasibility, patient selection, biomarker alignment, and sponsor-facing trial strategy.

Trial landscape analysis
Patient matching strategy
Inclusion / exclusion criteria review
Biomarker-defined eligibility
Recruitment and feasibility risk assessment

Scientific Due Diligence & Investment Advisory

We help investors, founders, and strategic partners evaluate the scientific and clinical credibility of biotech, AI-health, oncology, and precision medicine opportunities.

Scientific and translational due diligence
Biomarker and mechanism review
Clinical feasibility evaluation
AI/data moat assessment
Investor memo and risk assessment support

AI / Data Product Advisory

We advise AI-health and biomedical technology teams on clinical use-case prioritization, data strategy, product positioning, and investor-facing AI narratives.

Clinical use-case definition
Data asset assessment
AI workflow and product strategy
Competitive positioning
Investor-ready AI value story

Translational Research & Evidence Generation

We help academic and industry teams turn complex biomedical data into credible evidence packages for grants, manuscripts, partnerships, clinical development, and commercialization.

Multi-omics and single-cell interpretation
Biomarker discovery and validation strategy
Grant and manuscript strategy
Preliminary data package development
Academic-to-commercial translation

Who We Serve

Built for decision makers moving science, products, and capital forward.

Biotech & Pharma

For teams developing oncology, precision medicine, biomarker, therapeutic, or diagnostic programs.

AI-Health Startups

For founders building AI products in clinical trial intelligence, patient matching, drug development, real-world evidence, or biomedical knowledge mining.

Investors & Capital Partners

For investors and Wall Street-facing groups evaluating biotech, AI-health, oncology, or precision medicine opportunities.

Clinical Trial & CRO Teams

For teams seeking patient population strategy, trial feasibility assessment, recruitment intelligence, or biomarker-aligned trial design.

Academic Medical Centers

For cancer researchers and translational teams converting data and discoveries into grants, manuscripts, partnerships, or commercial opportunities.

Physician Founders & Translational Innovators

For clinicians and founders developing new biomedical products, clinical programs, diagnostics, or AI-enabled care models.

From Complex Data to Clear Decisions

Biomedical innovation often fails not because the science is weak, but because the strategy is unclear.

AiMi Health helps clients connect scientific evidence, clinical relevance, AI capability, and capital strategy into one coherent path forward.

Which patients should we target?

Which biomarkers can we trust?

Is the trial feasible?

Where can AI create real value?

What evidence is missing?

How should the science be positioned for investors, partners, and clinical stakeholders?

Representative Engagements

Executive-style support for the questions that determine momentum.

Representative examples are anonymized and designed to illustrate the types of strategic questions AiMi Health supports.

Turning a Biomarker Hypothesis into an Investor-Ready Strategy

Early-stage oncology biotech

Challenge

The client had a promising therapeutic concept but lacked a clear biomarker strategy, patient population definition, and scientific narrative for investor discussions.

Approach

AiMi Health reviewed disease biology, therapeutic rationale, public clinical trial landscape, biomarker evidence, and available multi-omics data. We identified the most defensible patient subgroup and clarified the scientific value proposition.

Deliverables

Biomarker strategy memo
Patient subgroup recommendation
Competitive landscape summary
Investor-facing scientific narrative
Next-step evidence generation roadmap

Outcome

The client gained a clearer strategy for fundraising, partnership discussions, and translational development.

Improving Clinical Trial Strategy with Patient Stratification

Clinical development team

Challenge

The client needed to refine trial feasibility and identify the most relevant patient population for a precision oncology study.

Approach

AiMi Health evaluated clinical trial databases, disease biology, biomarker prevalence, inclusion/exclusion criteria, competing studies, and patient stratification logic.

Deliverables

Trial landscape analysis
Patient population strategy
Biomarker-defined eligibility framework
Feasibility risk assessment
Clinical development recommendations

Outcome

The client obtained a clearer trial strategy and a stronger rationale for patient selection and recruitment planning.

Positioning an AI-Health Product for Real Clinical Value

AI-health startup

Challenge

The client had strong technical capabilities but needed a clearer clinical use case, data strategy, and investor-facing value proposition.

Approach

AiMi Health assessed the AI workflow, clinical pain points, target users, data availability, adoption risks, and competitive positioning.

Deliverables

AI use-case prioritization
Data asset and workflow assessment
Clinical value proposition
Product roadmap recommendations
Investor-facing positioning language

Outcome

The client gained a more focused story for product development, fundraising, and strategic partnership conversations.

Why AiMi Health

Scientific depth, AI fluency, clinical development awareness, and capital-facing strategy.

Scientific Depth

Deep experience across cancer research, computational biology, multi-omics, translational medicine, and biomarker strategy.

AI and Data Fluency

Expertise in AI/ML, clinical data, biomedical knowledge mining, multi-omics interpretation, and AI-enabled evidence generation.

Clinical and Translational Strategy

Ability to connect biology and data to patient populations, trial feasibility, clinical endpoints, and development decisions.

Capital-Aware Communication

Experience translating complex science into narratives that investors, sponsors, partners, and executive teams can understand and act on.

Founder-led advisory

Dr. Jade Zhou

Strategic advisor translating oncology, AI-enabled biomedical data, and clinical evidence into due diligence, development strategy, product positioning, and investment-ready scientific narratives.

OncologyAI/MLMulti-omicsCapital advisory

About AiMi Health

Boutique advisory for biomedical teams making consequential decisions.

AiMi Health is a boutique advisory firm focused on AI, precision medicine, biotech strategy, clinical trial intelligence, and capital advisory.

We work with biotech companies, pharma teams, AI-health startups, clinical researchers, CROs, investors, and strategic partners who need to make high-stakes decisions based on complex biomedical science and data.

Our mission is to help promising biomedical innovations become scientifically credible, clinically actionable, commercially positioned, and investment-ready.

Dr. Zhou has worked across academic cancer centers, translational research programs, AI and precision medicine education, and biotech-facing advisory projects. Her work bridges deep biomedical science with practical decision-making for drug development, clinical trials, investment, and commercialization.

Start a Conversation

Work With AiMi Health

Selected advisory engagements for scientific, clinical, AI, and investment strategy.

AiMi Health works with selected clients on high-value scientific, clinical, AI, and investment strategy projects.

To discuss a potential engagement, please send a brief description of your organization, project stage, key challenge, and desired timeline.

Oncology and precision medicine

AI-enabled clinical development

Biomarker and patient stratification strategy

Clinical trial intelligence

Scientific due diligence for biotech investment

Fundraising, partnership, or investor-ready evidence packages

AI-health product strategy

Email AiMi Health